EPO and leukemia: Accordingly, we determined that combination of mTOR and JAK2 inhibitor resulted in significant synergism concerning the inhibition of proliferation and colony formation of mouse and human JAK2V617 mutated leukemia cell lines and prevented at very low nanomolar concentration the formation of EPO-independent erythroid colonies.